BioNJ’s 13th Annual C-Suite Summit: A Premier Lineup & Bold Agenda

TRENTON, N.J., Oct. 9, 2025 /PRNewswire/ — BioNJ will host its Thirteenth Annual C-Suite Summit on Thursday, October 30, 2025, at the Bridgewater Marriott. This premier event convenes top executives from across the life sciences spectrum — from emerging startups to established global players, representing both public and private organizations at various stages of growth. As the industry contends with a fast-moving landscape marked by AI-powered advancements, shortened product lifecycles, economic uncertainty and geopolitical shifts, the Summit offers a valuable platform for strategic insights, candid conversations and high-level connections.

“With built-in networking opportunities — including direct access to speakers — this event fosters authentic dialogue and lasting relationships among executive decision-makers and forward-thinking innovators,” said Debbie Hart, President and CEO of BioNJ. “It’s a pivotal moment to reflect, regroup and reimagine what’s possible for the future of life sciences.”

The speaker roster, featuring world-class leaders, includes:

• Liz Barrett, Chief Executive Officer, UroGen Pharma
• Mark Campbell, CEO, Civia Health
• Michael Cantor, M.D., Vice President, Data Technology & Innovation, Regeneron
• Nick Downing, M.D., Managing Director, Bain Capital Life Sciences
• Nick Garlow, Managing Director, Rational 360
• Laurie Gery, Head, Business Development & Licensing, Vaccines, Sanofi
• Hisham Hamadeh, Ph.D., Senior Vice President, Global Head, Data, Digital & AI, Genmab
• Debbie Hart, President & CEO, BioNJ
• Ashutosh Katiyar, Executive Director, Commercial Strategy, Insights & Analytics, Regeneron
• Matthew B. Klein, M.D., M.S., F.A.C.S., Chief Executive Officer, PTC Therapeutics
• David Kuninger, M.D., Director, R&D, Thermo Fisher Scientific
• Emer Leahy, Ph.D., MBA, President & CEO, PsychoGenics & Chair, BioNJ
• Evan Lippman, Executive Vice President, Business Development, Teva Pharmaceuticals
• Christine Ann Miller, former CEO, Melinta Therapeutics
• Clive Meanwell, M.D., Ph.D., Chairman, Population Health Partners
• Chris Mortko, Ph.D., MBA, Vice President, Head Search & Evaluation, Business Development & Licensing, Merck & Co.
• Tim Opler, Ph.D., Managing Director, Stifel
• Emilio Ragosa, Partner & Managing Partner, DLA Piper
• Deiva Ramachandran, Ph.D., Partner, IBM
• George Santo, CFA, Managing Director, Head, Northeast Life Sciences – Middle Market Commercial Banking., J.P. Morgan
• Eduardo Schur, US Health Sciences & Wellness Commercial Strategy and R&D Lead, EY
• Nauman Shah, Global Head, J&J Innovative Medicine Business Development, Johnson & Johnson
• Arda Ural, Ph.D., Americas Life Sciences Leader, EY

The action-packed agenda includes these topics:

• Transforming Through Turbulence: How Culture-Driven Leadership Creates Strategic Options
• Making Sense of the Storm: Navigating Biopharma’s Challenging Financial Landscape
• How Biopharma Leaders are Staying Agile in the Current Environment
• Implications of Generative AI in Biopharma
• Accelerating Patient-Centric Innovation in R&D
• Evolving Capital Markets & Implications for Biopharma Ecosystem
• Navigating the Future of Deal Making in Biopharma

Click here
 for the full agenda.

“In this unprecedented era of policy challenges and industry scrutiny, the Summit serves as a crucial platform for leaders to unite and safeguard the future of innovation while expanding patient access,” said Hart. “We hope all stakeholders will join us for this essential conversation.”

Click here
 to register. Registration is $695 for BioNJ Members and $895 for Future Members. (Note: The Summit is closed to Media.) 

Contact
Randi Bromberg
Sr. Vice President, Communications and Marketing
O) 609-890-3185
C) 609-955-1067
RBromberg@BioNJ.org

View original content to download multimedia:https://www.prnewswire.com/news-releases/bionjs-13th-annual-c-suite-summit-a-premier-lineup–bold-agenda-302578794.html

SOURCE BioNJ